Paradoxes of adherence and drug resistance to HIV antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 696-699

  Bangsberg, David R ^a   Moss, Andrew R ^a   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug users; Non nucleoside reverse transcriptase inhibitors; Protease inhibitors; Public health; Resource constrained countries

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; POVERTY; PUBLIC HEALTH; RISK;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HUMANS; PATIENT COMPLIANCE; PUBLIC HEALTH;

EID: 2442689168     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh162     Document Type: Article

References (37)

1. Sontag, D. & Richardon, L. (1997). Doctors withhold HIV pill regimen from some. New York Times, 2 March 1997, p. A1.
2. Altice, F. L. & Friedland, G. H. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine 129, 503-5.
3. Friedland, G. H. & Williams, A. (1999). Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 13, Suppl. 1, S61-72.
4. Wainberg, M. A. & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association 279, 1977-83.
5. Bangsberg, D., Tulsky, J. P., Hecht, F M. et al. (1997). Protease inhibitors in the homeless. Journal of the American Medical Association 278, 63-5.
6. Harries, A. D., Nyangulu, D. S., Hargreaves, N. J. et al. (2001). Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358, 410-4.
7. Popp, D. & Fisher, J. D. (2002). First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world. AIDS 16, 676-8.
8. Jackson, P. (2003). Can Africa handle AIDS drugs? [Online]. http://news.bbc.co.uk/1/hi/health/3067345.stm (9 March 2004, date last accessed).
9. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D. et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14, 357-66.
10. Paterson, D. L., Swindells, S., Mohr, J. et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 133, 21-30.
11. Arnsten, J. H., Demas, P. A., Farzadegan, H. et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clinical Infectious Diseases 33, 1417-23.
12. McNabb, J., Ross, J. W., Abriola, K. et al. (2001). Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases 33, 700-5.
13. Bangsberg, D. R., Perry, S., Charlebois, E. D. et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181-3.
14. Hogg, R. S., Heath, K., Bangsberg, D. et al. (2002). Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 16, 1051-8.
15. Garcia de Olalla, P., Knobel, H., Carmona, A. et al. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30, 105-10.
16. Vanhove, G. F., Schapiro, J. M., Winters, M. A. et al. (1996). Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association 276, 1955-6.
17. Montaner, J. S., Reiss, P., Cooper, D. et al. (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Journal of the American Medical Association 279, 930-7.
18. Belkin, L. (1991). TB threat: not taking the medicine. Partly cured patients are the deadliest carriers. New York Times, 18 November 1991, p. B1.
19. Walsh, J. C., Pozniak, A. L., Nelson, M. R. et al. (2002). Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. Journal of Acquired Immune Deficiency Syndromes 30, 278-87.
20. Howard, A., Arnsten, J., Gardner, L. et al. (2002). Lack of multi-drug resistance in nonresponders to antiretroviral therapy with poor adherence. In First International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2002. Abstract 604. International AIDS Society, Stockholm, Sweden.
21. Gallego, O., de Mendoza, C., Perez-Elias, M. J. et al. (2001). Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 15, 1701-6.
22. Miller, L., McCutchan, J., Keiser, P. et al. (2003). The impact of medication adherence. Antiviral Therapy 8, S167.
23. Bangsberg, D. R., Charlebois, E. D., Grant, R. M. et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17, 1925-32.
24. Bangsberg, D. R., Kagay, C., Porco, T. et al. (2004). Modeling the relationship between adherence and the accumulation of protease inhibitor drug resistance mutations. Journal of Infectious Diseases, in press.
25. Harrigan, R., Dong, W., Alexander, C. et al. (2003). The association between drug resistance and adherence determined by two independent methods in a large cohort of drug naive individuals starting triple therapy. In Second International Conference on HIV Treatment and Pathogenesis, Paris, 2003, Abstract LB12. IAS International AIDS Society, Stockholm, Sweden.
26. King, M., Brun, S., Tschampes, J. et al. (2003). Exploring the effects of adherence on resistance: use of local linear regression to reveal relationships between adherence and resistance in antiretroviral-naive patients treated with lopinavir/ritonavir or nelfinavir. Antiviral Therapy 8, S118.
27. Bangsberg, D. & Deeks, S. (2003). Is average adherence to HIV antiretroviral therapy enough? Journal of General Internal Medicine 17, 812-3.
28. Walmsley, S., Bernstein, B., King, M. et al. (2002). Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 346, 2039-46.
29. Staszewski, S., Morales-Ramirez, J., Tashima, K. T. et al. (1999). Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 341, 1865-73.
30. Kuritzkes, D., Ickovics, J., Bassett, R. et al. (2001). HIV-1 drug resistance and medication adherence in patients receiving NRTIs. In Fifth International Workshop on HIV Resistance & Treatment Strategies, Scottsdale, 2001. Abstract 84.
31. Parienti, J., Veronique, M., Descampes, D. et al. (2004). Predictors of virologic failure and resistance in HIV-1 infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases, in press.
32. Sethi, A. K., Celentano, D. D., Gange, S. J. et al. (2003). Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases 37, 1112-8.
33. Jackson, J. B., Becker-Pergola, G., Guay, L. A. et al. (2000). Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14, F111-5.
34. Clarke, J. R., Braganza, R., Mirza, A. et al. (1999). Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. Journal of Medical Virology 59, 364-8.
35. Mellors, J., Palmer, S., Nissley, D. et al. (2003). Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations. Antiviral Therapy 8, S166.
36. Grant, R. M., Hecht, F M., Warmerdam, M. et al. (2002). Time trends in primary HIV-1 drug resistance among recently infected persons. Journal of the American Medical Association 288, 181-8.
37. Little, S. J., Holte, S., Routy, J. P. et al. (2002). Anti retroviral-drug resistance among patients recently infected with HIV. New England Journal of Medicine 347, 385-94.